MHC
GILD icon

May Hill Capital’s Gilead Sciences GILD Stock Holding History

May Hill Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$324K Buy
2,563
+128
+5% +$16.9K 0.07% 176
2026
Q1 		$339K Buy
2,435
+149
+7% +$20.9K 0.09% 164
2025
Q4 		$281K Buy
2,286
+88
+4% +$10.7K 0.08% 158
2025
Q3 		$244K Buy
2,198
+54
+3% +$6.14K 0.07% 167
2025
Q2 		$238K Buy
2,144
+111
+5% +$11.8K 0.08% 165
2025
Q1 		$228K Buy
+2,033
New +$210K 0.09% 157

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

May Hill Capital's GILD Position: Q2 2026 in Review

May Hill Capital increased its Gilead Sciences (GILD) stake by 5.3% in Q2 2026, buying an estimated $16.9K and bringing the position to 2,563 shares worth $324K. The position accounts for 0.07% of the portfolio, ranked #176.

May Hill Capital first reported a position in GILD in Q1 2025 and has held it in 6 quarters since. The position peaked at $339K in Q1 2026. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • May Hill Capital held 2,563 shares of Gilead Sciences worth $324K as of Q2 2026.
  • May Hill Capital bought 128 Gilead Sciences shares in Q2 2026, an estimated $16.9K.
  • Gilead Sciences made up 0.07% of May Hill Capital's portfolio in Q2 2026, its #176 holding.
  • May Hill Capital first reported a position in Gilead Sciences in Q1 2025 and has held it in 6 quarters since.
  • May Hill Capital's Gilead Sciences position peaked at $339K in Q1 2026.
  • 2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on May Hill Capital's 13F filing for Q2 2026, filed 7 Aug 2026.